ArticleACS omega2024
Targeting Metabolic Syndrome Pathways: Carrot microRNAs As Potential Modulators.
Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Peripheral and Central miRNA Signatures in Alzheimer's Disease: Tissue-Specific Variability, Sex-Associated Differences, and Implications for Blood-Based Biomarkers.International journal of molecular sciences · 2026Review
- Synthetic Mimics of Wound-Induced Carrot MicroRNAs Affect Lipid Metabolism in Cultured Adipocytes.Nutrients · 2025Article
- Involvement of miRNAs in the Cluster of Metabolic Factors of MetS: Nutrition-Genome-MetS Axis.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome is a condition characterized by metabolic alterations that culminate in chronic noncommunicable diseases of high morbidity and mortality, such as cardiovascular diseases, type 2 diabetes, nonalcoholic fatty liver disease, and colon cancer. Developing new therapeutic strategies with a multifactorial approach is important since current therapies focus on only one or two components of the metabolic syndrome. In this sense, plant-based gene regulation represents an innovative strategy to prevent or modulate human metabolic pathologies, including metabolic syndrome. Here, using a computational and systems biology approach, it was found that carrot microRNAs can modulate key BMPs/SMAD signaling members, C/EBPs, and KLFs involved in several aspects associated with metabolic syndrome, including the hsa04350:TGF-beta signaling pathway, hsa04931:insulin resistance, hsa04152:AMPK signaling pathway, hsa04933:AGE-RAGE signaling pathway in diabetic complications, hsa04010:MAPK signaling pathway, hsa04350:TGF-beta signaling pathway, hsa01522:endocrine resistance, and hsa04910:insulin signaling pathway. These data demonstrated the potential applications of carrot microRNAs as effective food-based therapeutics for obesity and associated metabolic diseases.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.